Japanese SPF sends message that it is more than just a patent assertion entity with new drug discovery collaboration 03 Nov 16
IP Bridge (IPB) – the company that operates Japan’s sovereign patent fund (SPF) – announced last week that it has signed a drug discovery deal with Kyushu University, indicating that it is aiming beyond straight monetisation activities to fulfil its originally stated objectives of facilitating open innovation and putting Japan’s vast stockpile of dormant intellectual property to work.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM is a high quality magazine with in-depth articles about intellectual asset management not found in any other publication. It adds value to our profession!
Director of the office of technology licensing
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email